GLP-1 drugs like Ozempic, Wegovy, and Mounjaro have been wildly successful. But as popular as they are, Americans still have very negative feelings about the people using them. In this month’s Highlight cover story, Dylan Scott explains why ‘Ozempic stigma’ hasn’t gone away, how it’s impacting GLP-1 users, and whether it could begin to fade as more and more people take the drugs. Also in this issue: How to tolerate uncertainty. What rent freezes could mean for renters. Good news about declining road deaths. And the coming AI wealth boom. By Shayla Love The simple idea that helped prevent millions of traffic deathsBy Bryan WalshComing August 4 The one thing Ozempic still can’t fixBy Dylan ScottComing August 4 How to tolerate uncertainty in a world that’s full of itBy Elizabeth WeingartenComing August 5 The truth about rent controlBy Marina BolotnikovaComing August 5 Rise of the AI-ristocracyBy Sara HerschanderComing August 6
Welcome to the August issue of The Highlight
Full Article
Original Source
Read the full article at Vox →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.